Table 1.
First author, year | Country | Setting | POI group | Control group | Follow up time | Number of events | Number of events |
Sample size | Sample size | (Incidence %) in POI group | (Incidence %) in Control group | ||||
Baba et al. 2010 [21] | Japan | Jichi Medical School population-based prospective study | N = 237 | N = 2171 | Mean of 10.8 y | Stroke: 10 (4.2) | Stroke: 76 (3.5) |
Choi et al. 2005 [22] | Korea | The Korean Elderly Pharmacoepidemiologic population-based Cohort study | N = 84 | N = 2555 | 27,936 person-y (5 y) | Stroke: 3 (3.5) | Stroke: 87 (3.4) |
Cooper et al. 1998 [23] | USA | National Health and Examination Survey Epidemiologic Follow-up study | N = 115 | N = 1475 | Mean of 4 y | Death due to any cardiovascular events: 9 (7.83) | Death due to any cardiovascular events: 71 (4.8) |
Dam et al. 2019 [24] | 10 European countries | EPIC-CVD, a case–cohort study, which includes data from 23 centres from 10 European countries | N = NM | N = NM | Median of 11 y | Coronary heart disease: 364 (43.8%) | Coronary heart disease: 1563 (45.4%) |
Gallagher et al. 2011 [25] | China | Shanghai population-based Cohort study | N = 16,029 | N = 450,359 | Median of 10 y | Coronary heart disease: 7 (0.04) | Coronary heart disease: 175 (0.04) |
Stroke: 43 (0.27) | Stroke: 986 (0.22) | ||||||
Hong et al. 2007 [26] | South Korean | Kangwha population-based Cohort study | N = 198 | N = 948 | Median of 15.8 y | Death due to any cardiovascular events: 27 | Death due to any cardiovascular events: 101 |
Honigberg et al. 2021 [27] | UK | UK Biobank population-based Cohort study | N = 5201 | N = 86,557 | Median of 11.1 y | PH: 38 (0.73%) | PH: NM |
HR: 2.36, 95% CI: 1.49–3.73 | |||||||
Honigberg et al. 2019 [28] | UK | UK Biobank population-based Cohort study | N = 5548 | N = 138,712 | Median of 7 y | Coronary heart disease: 124 (2.24) | Coronary heart disease: 1646 (1.19) |
Heart failure: 50 (0.9) | Heart failure: 722 (0.5) | ||||||
Stroke: 35 (0.6) | Stroke: 584 (0.4) | ||||||
HTN: 301 (5.4) | HTN: 5007 (3.6) | ||||||
Heart valve disease: 44 (0.7) | Heart valve disease: 604 (0.4) | ||||||
Honigberg et al. 2021 [29] | UK | UK Biobank population-based Cohort study | N = 1305 | N = 18,301 | Median of 7-13.1 y | Coronary heart disease: 162 (12.4) | Coronary heart disease 1568 (8.5) |
Hu et al. 1999 [30] | USA | Nurses’ Health study, population-based Cohort study | N = NM | N = NM | Median of 18 y | Coronary heart disease: 18 | Coronary heart disease: 375 |
Stroke: 4 | Stroke: 182 | ||||||
Ley et al. 2017 [31] | USA | Nurses’ Health study, population-based Cohort study | N = NM | N = NM | 1,467,987 person-y | Coronary heart disease: 177 | Coronary heart disease: 1306 |
Stroke: 163 | Stroke: 1239 | ||||||
Li et al. 2013 [32] | USA | Black Women’s Health study, population-based Cohort study | N = 586 | N = 4747 | Median of 13 y | Death due to any cardiovascular events: 15 | Death due to any cardiovascular events: 70 |
Løkkegaard et al. 2006 [33] | Denmark | Danish Nurse | N = 380 | N = 8186 | Median of 5 y | Coronary heart disease: 7 | Coronary heart disease: 3 |
population-based Cohort study | HR: 2.1, 95% CI: 1.3–3.5 | ||||||
Ossewaarde et al. 2005 [34] | Netherlands | breast cancer screening cohort, population-based Cohort study | N = 454 | N = 5753 | Median of 17 y | Death due to any cardiovascular events: 50 | Death due to any cardiovascular events: 445 |
van der Schouw et al. 1996 [35] | Netherlands | DOM project, population-based Cohort study | N = 459 | N = 5741 | Median of 20 y | Death due to any cardiovascular events: 43 | Death due to any cardiovascular events: 391 |
Welten et al. 2021 [36] | Netherlands | (European Prospective Investigation into Cancer | N = 2407 | N = 5353 | Median of 15 y | Stroke: 121 | Stroke: 310 |
and Nutrition–Netherlands) population-based Cohort study |
N, number; NM, not mentioned; y, year. HR, hazard ratio; CI, confidence interval; POI, premature ovarian insufficiency; EPIC-CVD, European Prospective Investigation into Cancer and Nutrition (EPIC) study; PH, pulmonary hypertension; HTN, hypertension; DOM, Diacnostisch Onderzoek (investigation Mammacarcinoom).